Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Zinc finger protein 787 is a human transcription factor characterized by multiple zinc finger domains. Experimental studies suggest ZNF787 acts as a negative regulator of tight junction proteins such as occludin and claudin-5, particularly in the context of increased blood-brain barrier permeability in Alzheimer's disease models. Mechanistic data indicate ZNF787 interacts with HDAC1 to suppress transcription of tight junction genes, thereby modulating blood-brain barrier integrity and inflammation. ZNF787 may also be involved in genetic fusion events in cancer, but is not established as a direct therapeutic target.
Not applicable (No drugs targeting ZNF787 have been described; its own function is transcriptional regulation, particularly repressing tight junction genes through HDAC1 interaction)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Zinc finger protein 787 (ZNF787).